First drug repurposing trial for COVID-19 falls flat

By Anette Breindl

The first attempt at using existing drugs to treat patients infected with SARS-CoV-2 has yielded disappointing results.

In 200 hospitalized patients with severe COVID-19, a 14-day regimen of twice-daily treatment with Kaletra/Aluvia (lopinavir/ritonavir, Abbvie Inc.) did not hasten recovery when added to the standard of care. Chinese clinicians led by Bin Cao of the National Clinical Research Center for Respiratory Diseases reported their findings in the March 19, 2020, issue of The New England Journal of Medicine.

Lopinavir is a protease inhibitor, while ritonavir increases the half-life of lopinavir by inhibiting its metabolism. The drug was tested because screening studies had flagged it as having activity against MERS-CoV, which has led to a clinical trial of a combination of Kaletra/Aluvia and interferon-beta for the treatment of MERS-CoV in the Kingdom of Saudi Arabia.

In the COVID-19 trial, 199 patients were treated, split evenly between drug and standard-of-care groups. The study’s primary endpoint, time to improvement, was the same between the two groups, both of which took 16 days to improve. Mortality and viral load at various time points were also not different.

In an editorial published alongside the paper, Lindsey Baden, of Harvard Medical School, and Eric Rubin, of the Harvard TH Chan School of Public Health, wrote that “the results for certain secondary endpoints are intriguing,” but also acknowledged that those results were hard to interpret, due to a mix of trial size, possible differences in illness severity at baseline, and the fact that the trial was randomized but not blinded.

And if certain endpoints were intriguing, others were discouraging. In particular, viral loads did not differ between the groups, tellingly so, according to Baden and Rubin. “Since the drug is supposed to act as a direct inhibitor of viral replication, the inability to suppress the viral load and the persistent detection of viral nucleic acid strongly suggest that it did not have the activity desired,” they wrote. “Thus, although some effect of the drug is possible, it was not easily observed.”

It is possible that larger trials will yet uncover an effect of Kaletra/Aluvia. But for now, perhaps the best hope is that other drugs will work better – in particular, remdesivir (Gilead Sciences Inc.), which was originally developed for Ebola virus disease, but proved less effective there than several other options.

A paper in the Jan. 10, 2020, issue of Nature Communications investigated the effects of Aluvia on MERS-CoV in mouse experiments, where it showed ho-hum effects. The authors of the Nature Communications paper reported that “prophylactic [Kaletra/Aluvia plus interferon-beta] slightly reduces viral loads without impacting other disease parameters.”

But remdesivir was more effective. “Both prophylactic and therapeutic [remdesivir] improve pulmonary function and reduce lung viral loads and severe lung pathology” in a mouse model of MERS, the authors reported.

Remdesivir is in both an NIH-sponsored clinical trial and a Japanese-Chinese trial as potential COVID-19 treatment, after a January case report of a patient who showed rapid improvement after he was treated with the drug for COVID-19.

Though the Kaletra/Aluvia trial’s results were not as hoped, Baden and Rubin noted that the trial itself was an encouraging bit of news, as well as a “heroic effort…. As we saw during the 2014 Ebola outbreak in West Africa, obtaining high-quality clinical trial data to guide the care of patients is extremely difficult in the face of an epidemic, and the feasibility of a randomized design has been called into question. Yet Cao’s group of determined investigators not only succeeded but ended up enrolling a larger number of patients (199) than originally targeted.”

Coronavirus update: Virus could live up to 24 hours on cardboard, 3 days on plastic and steel, study says

Coronavirus could live up to three days on a plastic or stainless steel doorknob, researchers found.

A preliminary study released last week also showed that the virus could be aerosolized, meaning it could potentially live in the air. It could live up to three days on some surfaces.

Though it’s widely acknowledged that coronavirus could be spread via respiratory droplet — the result of coughing or sneezing — there’s not much information yet on how the virus lives on surfaces or in the air.

The new research could inform cleaning recommendations and other measures taken to reduce community spread.

The U.S. Centers for Disease Control and Prevention recommend routine cleaning of high-touch surfaces, like door handles, high-backed chairs, light switches and remote controls.

The study, released last week, is not yet peer-reviewed. That means that other experts have not had the chance to check the quality of the research, and its not advised that doctors use it in a clinical setting. But as people try to cope with the disease, it’s being widely read.

Here’s how long the study indicated the virus could live on various surfaces:

The air: Researchers found the virus could be detected in aerosols up to 4 hours after it was sprayed.

Copper: Up to 4 hours

Cardboard: Up to 24 hours

Plastic: 2-3 days

Stainless steel: 2-3 days

https://www.cleveland.com/news/2020/03/coronavirus-update-virus-could-live-up-to-24-hours-on-cardboard-3-days-on-plastic-and-steel-study-says.html?utm_source=Newsletter&utm_medium=Newsletter%20-%20Wake%20Up&utm_campaign=Newsletter:%20The%20Wake%20Up

Ancient cave carving depicts six-legged mantis-man

Researchers have discovered a unique petroglyph, depicting what appears to be a six-legged mantis-man, at the Teymareh rock art site in Iran.

Invertebrates are rarely found in rock carvings, so the archaeologists on the project recruited entomologists to help them determine what kinds of creatures might have inspired the motif. Researchers looked at several six-legged species that prehistoric artists might have come across in central Iran.

The motif measures just 5.5 inches in length, and though it was discovered in 2017, its small size and unusual shape made it difficult to identify. In addition to boasting six legs, the creature features large eyes and enlarged pincher-like forearms.

The entomologists on the study identified an extension on the creature’s head that matches local praying mantis species belonging to the genus Empusa.

Scientists estimate the rock art is between 4,000 and 40,000 years old.

“The petroglyph proves that praying mantids have been astounding and inspiring humans since prehistoric times,” researchers wrote in the Journal of Orthoptera.

The figure isn’t a perfect representation of a Empusa mantis, as the middle limbs feature loops as a hands. Researchers linked the carving with a common petroglyph motif known as “Squatter Man,” which has been found at rock art sites around the world. The motif features a person flanked by circles.

Some researchers suggest the circles represent the atmospheric plasma discharges created by auroras.

The discovery of the latest petroglyph reinforces the theory, based on previous discoveries of half-mantid, half-human figures, that the mantis was a symbol for the supernatural.

“An example includes several prehistoric pictographs in southern Africa representing ‘mantis people’ with half-mantid bodies,” researchers wrote in their paper. “These, and the Iranian mantid petroglyph, bear witness that in prehistory, almost as today, praying mantids were animals of mysticism and appreciation.”

https://www.upi.com/Science_News/2020/03/16/Ancient-cave-carving-depicts-six-legged-mantis-man/9801584372927/?ls=4

Woman at Cleveland Hopkins International Airport claims she had coronavirus, prompts shutdown of TSA checkpoint


A woman falsely claimed she had coronavirus at a security checkpoint at Cleveland Hopkins International Airport, shutting down the checkpoint for 20 minutes, officials said.

By Adam Ferrise

A Los Angeles woman caused the temporary closure of a security checkpoint at Cleveland Hopkins Airport Sunday after she told a TSA agent that she contracted the coronavirus.

The woman licked her fingers as she handed her driver’s license to the agent, Cleveland police and the TSA said.

The 63-year-old woman was not arrested and criminal charges were not filed as of Monday afternoon. Police reports say the woman could face a charge of inducing panic.

The incident caused the checkpoint to close for 20 minutes for the area to be cleaned, according to police and a TSA spokeswoman. The TSA spokeswoman said the agency plans to pursue a civil citation against the woman, which could result in a fine.

The incident happened as coronavirus continues to spread in Ohio and Cuyahoga County. Of the 50 confirmed coronavirus cases in Ohio so far, 24 are in Cuyahoga County.

Airport spokeswoman Michele Dynia referred questions about airport operations to Cleveland’s Joint Information Center. A woman answering the phone there said she could not immediately answer any questions about the woman’s encounter with the agent.

The incident happened about 5:20 p.m. Sunday. The woman walked up to the TSA checkpoint, licked her fingers just before handing her driver’s license to a TSA agent, and said: “Good thing you are wearing gloves because I just licked my fingers and I have coronavirus,” according to police reports.

TSA agents called for the Cleveland fire and medics posted at the airport to respond. The woman denied telling the TSA agent she had coronavirus, but said she did lick her fingers and told the agent she was glad he was wearing gloves, police reports say. She told officers she had no health issues and did not have coronavirus.

An airline banned her from flying on Sunday, according to the TSA. TSA agents prohibited the woman from entering the airport for 24 hours, according to the police report.

https://www.cleveland.com/metro/2020/03/woman-at-cleveland-hopkins-international-airport-claims-she-had-coronavirus-prompts-shutdown-of-tsa-checkpoint.html

Scientists have discovered the origins of the building blocks of life


A fold (shape) that may have been one of the earliest proteins in the evolution of metabolism. Credit: Vikas Nanda/Rutgers University

Rutgers researchers have discovered the origins of the protein structures responsible for metabolism: simple molecules that powered early life on Earth and serve as chemical signals that NASA could use to search for life on other planets.

Their study, which predicts what the earliest proteins looked like 3.5 billion to 2.5 billion years ago, is published in the journal Proceedings of the National Academy of Sciences.

The scientists retraced, like a many thousand piece puzzle, the evolution of enzymes (proteins) from the present to the deep past. The solution to the puzzle required two missing pieces, and life on Earth could not exist without them. By constructing a network connected by their roles in metabolism, this team discovered the missing pieces.

“We know very little about how life started on our planet. This work allowed us to glimpse deep in time and propose the earliest metabolic proteins,” said co-author Vikas Nanda, a professor of Biochemistry and Molecular Biology at Rutgers Robert Wood Johnson Medical School and a resident faculty member at the Center for Advanced Biotechnology and Medicine. “Our predictions will be tested in the laboratory to better understand the origins of life on Earth and to inform how life may originate elsewhere. We are building models of proteins in the lab and testing whether they can trigger reactions critical for early metabolism.”

A Rutgers-led team of scientists called ENIGMA (Evolution of Nanomachines in Geospheres and Microbial Ancestors) is conducting the research with a NASA grant and via membership in the NASA Astrobiology Program. The ENIGMA project seeks to reveal the role of the simplest proteins that catalyzed the earliest stages of life.

“We think life was built from very small building blocks and emerged like a Lego set to make cells and more complex organisms like us,” said senior author Paul G. Falkowski, ENIGMA principal investigator and a distinguished professor at Rutgers University-New Brunswick who leads the Environmental Biophysics and Molecular Ecology Laboratory. “We think we have found the building blocks of life—the Lego set that led, ultimately, to the evolution of cells, animals and plants.”

The Rutgers team focused on two protein “folds” that are likely the first structures in early metabolism. They are a ferredoxin fold that binds iron-sulfur compounds, and a “Rossmann” fold, which binds nucleotides (the building blocks of DNA and RNA). These are two pieces of the puzzle that must fit in the evolution of life.

Proteins are chains of amino acids and a chain’s 3-D path in space is called a fold. Ferredoxins are metals found in modern proteins and shuttle electrons around cells to promote metabolism. Electrons flow through solids, liquids and gases and power living systems, and the same electrical force must be present in any other planetary system with a chance to support life.

There is evidence the two folds may have shared a common ancestor and, if true, the ancestor may have been the first metabolic enzyme of life.

https://phys.org/news/2020-03-scientists-blocks-life.html

AI can pick out specific odours from a combination of smells


A new AI can detect odours in a two-step process that mimics the way our noses smell

An AI can sniff out certain scents, giving us a glimpse of how our nose might work in detecting them.

Thomas Cleland at Cornell University, New York, and Nabil Imam at tech firm Intel created an AI based on the mammalian olfactory bulb (MOB), the area of the brain that is responsible for processing odours. The algorithm mimics a part of the MOB that distinguishes between different smells that are usually present as a mixture of compounds in the air.

This area of the MOB contains two key types of neuron: mitral cells, which are activated when an odour is present but don’t identify it, and granule cells that learn to become specialised and pick out chemicals in the smell. The algorithm mimics these processes, says Imam.

Cleland and Imam trained the AI to detect 10 different odours, including those of ammonia and carbon monoxide. They used data from previous work that recorded the activity of chemical sensors in a wind tunnel in response to these smells.

When fed that data, the AI learns to detect that a smell is present based on the sensors’ responses to the chemicals, and then goes on to identify it on the basis of the patterns in that data. As it does so, the AI has a spike of activity analogous to the spikes of electrical activity in the human brain, says Imam.

The AI refined its learning over five cycles of exposure, eventually showing activity spikes specific to each odour. The researchers then tested the AI’s ability to sniff out smells among others that it hadn’t been trained to detect. They considered an odour successfully identified when the AI’s fifth spike pattern matched or was similar to the pattern produced by the sensors.

The AI got it almost 100 per cent correct for eight of the smells and about 90 per cent correct for the remaining two. To test how it might identify odorous contaminants in the environment, the researchers blocked 80 per cent of the smell signal to mimic more realistic scenarios. In these tests, the AI’s accuracy dipped to less than 30 per cent.

“I think the link [to the MOB] is quite strong – this algorithm might be an explanation to how it works in the human nose, to some abstraction,” says Thomas Nowotny at the University of Sussex, UK. But the AI’s ability to solve real life problems, such as detecting bombs by picking out hazardous smells associated with them, is still some way off, he says.

Read more: https://www.newscientist.com/article/2237534-ai-can-pick-out-specific-odours-from-a-combination-of-smells/#ixzz6GxdKsmxq

Italian man wears isolation donut

A man in Italy has been spotted wearing what has been described as a social-distancing “doughnut” in order to ensure he stays a safe distance from others during the country’s outbreak of COVID-19.

In the footage, which was shared online last week, the man is seen wearing a large yellow saucer, which has been suspended around his waist with two arm straps.

“And this would be a safe distance?” another man can be heard asking him in Italian, to which the doughnut-wearing citizen confirms.

“For coronavirus,” the man responds.

The video was reportedly captured in Rome’s Mercato Testaccio, a popular food market located in the Testaccio neighborhood south of the city’s center, according to a tag placed on the video.

Nowhere in the footage does the man refer to the apparatus as a “doughnut,” although that name had been applied by social media viewers, as well as Popular Mechanics.

Twitter users soon declared the man “un genio” (a genius) and praised him for his ingenuity, while another asked why the World Health Organization hadn’t thought of this idea first.

Despite the jokes, the practice of “social distancing” amid the ongoing coronavirus pandemic has been recommended by health agencies to stem the spread of COVID-19.

“Social distancing for COVID-19 means avoiding places or gatherings where you are likely to be exposed to respiratory droplets from others – directly or on surfaces,” Dr. Jill Grimes, an urgent care physician at The University of Texas, had previously told Fox News. “We know this virus is spread primarily by these droplets, up to a distance of roughly six feet (from a cough or a sneeze) and so avoiding areas where people are physically closer than six feet is key.”

Possible Biological Explanations for Kids’ Escape from COVID-19


Infected children may harbor SARS-CoV-2 while showing less-severe symptoms than adults. Their young immune systems, ACE2 receptor levels, and even exposure to other coronaviruses might play a role in their resilience.

by Anthony King

Since SARS-CoV-2, the virus responsible for the COVID-19 pandemic, was first recognized as a close cousin of the virus that caused the SARS outbreak of 2003, scientists have looked to the experience of that earlier epidemic to glean insight into the current global health crisis.

Kids were largely unaffected in the original SARS outbreak. In Hong Kong, no one under the age of 24 years died, while more than 50 percent of patients over 65 succumbed to the infection. Globally, less than 10 percent of those diagnosed with SARS were children, and only 5 percent of them required intensive care.

“There were repeated incursions from animals to humans, with both SARS and MERS, and the assumption by many was maybe children are just not exposed to the infected civet cats or camels,” says virologist Kanta Subbarao of the Doherty Institute in Melbourne, Australia.

A very similar pattern has been observed with the new outbreak of COVID-19. Within Wuhan, no children tested positive between November 2019 and the second week of January, and the elderly proved particularly vulnerable. The Chinese Centers for Disease Control and Prevention reported in mid-February that out of 44,672 confirmed cases of COVID-19, 86.6 percent were between 30 and 79 years of age. The oldest among them were at greatest risk of death. And in a study of 1,099 patients in China, just 0.9 percent of confirmed cases were under the age of nine, while only 1.2 percent were between 10 and 19 years old.

Now, evidence is emerging that while few children suffer severely from COVID-19, they do get infected. A recent study even found evidence of viral excretion in children from rectal swabs. “At the moment it doesn’t seem to be causing much in the way of serious disease in young people, particularly children,” says virologist Robin Shattock of Imperial College London. However, he adds, “it is quite likely that children are an important source of the virus.”

“There is good evidence that children get infected and have a fairly high titre of virus but just don’t have serious disease,” agrees Ralph Baric, a coronavirus researcher at the University of North Carolina at Chapel Hill. He saw a similar phenomenon in his mouse studies with the original SARS coronavirus (SARS-CoV). Although SARS-CoV can replicate fairly well, “younger animals are really resistant to infection in terms of the disease,” he says. When Baric tested older animals, he says, the severity of SARS illnesses rose. In one experiment, one-fifth of mice infected with SARS aged 3–4 weeks died, whereas all of the mice 7–8 weeks old died.

Subbarao has also found that young adult mice, at six weeks old, can clear SARS-CoV with no significant clinical symptoms. “When we used the same virus in 12-month-old mice, which is by no means really old, there were more clinical signs,” she says. These results indicate that both the original SARS-CoV and the one circulating now may infect children, but not make them ill. “The animal data supports the idea that they are infected but do not develop disease, because our young mice have the same levels of virus as old mice but do not get sick,” says Stanley Perlman, an immunologist at the University of Iowa. “It is not a question of infection.”

The work on mice is now being supported by emerging epidemiological data. A preprint posted to medRxiv on March 4 analyzed 391 COVID-19 cases and 1,286 of their close contacts. The authors concluded that children are at a similar risk of infection as the general population, though less likely to have severe symptoms.

An aging immune system

One explanation for the correlation between age and disease severity is that as humans’ immune systems age, more cells become inactive. “As you age, your immune system undergoes senescence and loses its capacity to respond as effectively or be regulated as effectively,” says Baric.

Another explanation, which Perlman favors, is tied to the aging lung environment. In order for individuals not to easily develop asthma or overreact to environmental irritants such as pollen or pollution, aged lungs counter the usual immune reaction with some tamping down of inflammation. As a result, says Perlman, the lungs do not respond quickly enough to a viral infection. For instance, when his group makes the lungs of older mice more like those of young mice by altering prostaglandins, compounds that respond to tissue injury, “then the mice do well and they can clear the [SARS] infection and don’t get sick,” says Perlman.

In experiments reported in 2010, Perlman and his colleagues showed that T cells are especially important in clearing viruses from mice infected with SARS-CoV. “It is almost certain we need both an antibody- and T cell–response to do well” against COVID-19 infection, says Perlman. His suspicion is that the young immune system and its efficient T cells do a superior job of responding to SARS-CoV-2. A 2010 study led by Subbarao also stressed the importance of CD4+ helper T cells, which stimulate B cells to make antibodies against pathogens, in controlling SARS-CoV infection in mice.

“It could be that the type of T cell that dominates early in life is better at repelling this virus,” says immunologist Kingston Mills of Trinity College Dublin. He also proposes that young children’s higher production of a type of T cell called Th2 might guard against runaway inflammatory responses to SARS-CoV-2. Perlman doesn’t support the proposed role of a bias toward Th2 cells in the case of this viral infection, but he does agree that an immune overreaction is problematic.

“The innate response is delayed in the elderly, so ends up playing catch-up and is exuberant,” Perlman writes in an email to The Scientist.

ACE2 receptor

SARS-CoV and SARS-CoV-2 both use the same keyhole to enter cells, the ACE2 receptor. There’s an abundance of this receptor in cells in the lower lung, which may explain the high incidence of pneumonia and bronchitis in those with severe COVID-19 infection. A recent study showed that ACE2 is also highly expressed in the mouth and tongue, granting the virus easy access to a new host. ACE2 receptor abundance goes down in the elderly in all these tissues, but, counterintuitively, this might place them at a greater risk of severe illness.

This is because the ACE2 enzyme is an important regulator of the immune response, especially inflammation. It protects mice against acute lung injury triggered by sepsis. And a 2014 study found that the ACE2 enzyme offers protection against lethal avian influenza. Some patients with better outcomes had higher levels of the protein in their sera, and turning off the gene for ACE2 led to severe lung damage in mice infected with H5N1, while treating mice with human ACE2 dampened lung injury.

A fall in ACE2 activity in the elderly is partly to blame for humans’ poorer ability to put the brakes on our inflammatory response as we age, according to emailed comments from Hongpeng Jia of Johns Hopkins Medicine. Reduced abundance of ACE2 receptors in older adults could leave them less able to cope with SARS-CoV-2, says Baric, though the hypothesis still needs more research.

Exposure to other coronaviruses

There are four other coronaviruses that infect humans, with symptoms typical of a common cold. These viruses are common in children. “We don’t know which of them, if any, might provide some cross immunity,” says Subbarao. It could be that immunity to viral proteins, obtained from circulating “common cold” viruses, moderates the course of COVID-19.

This is a “hand-waving hypothesis,” Subbarao adds, but one that is worth testing. Recently, it has been suggested that plasma from people who’ve recovered from COVID-19 could be transfused into patients infected with SARS-CoV-2 to treat them.

“I don’t think anyone in the field knows why the disease is less robust in extremely young animals or humans,” Baric tells The Scientist. It is also still too early to know how much learned from the first SARS coronavirus applies to SARS-CoV-2. “SARS-CoV-1 will tell us a lot, but I think there is new information we are going to learn about SARS-CoV-2,” Perlman acknowledges.

https://www.the-scientist.com/news-opinion/possible-biological-explanations-for-kids-escape-from-covid-19-67273?utm_campaign=TS_DAILY%20NEWSLETTER_2020&utm_source=hs_email&utm_medium=email&utm_content=84840060&_hsenc=p2ANqtz-_QBhFeETnCdgO-hMkDQF0G0KlDcX_Lu5wb8FR6n0M2nggE4q841plJ_OtOZv-bbBKiOgV9emt0eX9q7t-0l6Og3pcCVQ&_hsmi=84840060

Regeneron and Sanofi speed Kevzara into coronavirus trials

Dive Brief:

Rheumatoid arthritis drug Kevzara will be used in an international study of patients infected with the new coronavirus and suffering from acute respiratory distress syndrome, Regeneron Pharmaceuticals and Sanofi announced Monday.

The trial will kick off in disease hotspot New York City, expanding to a total of 16 U.S. sites and enrolling 400 patients. The companies aim to study whether Kevzara can reduce fever and the need for supplemental oxygen in patients severely affected by COVID-19, the illness caused by the virus.

Roche’s Actemra, which has a similar mechanism of action, has been tested in Chinese patients and led to a decrease in fever and oxygen use, prompting the country to include it in treatment guidelines. The drug’s use shows the speed with which global public health officials are willing to consider using drugs off-label in order to address the coronavirus pandemic.

Dive Insight:

A vaccine to prevent infections of the novel coronavirus SARS-CoV-2 is likely a year or more away — at best — and treatments specifically designed to fight this virus or its complications are similarly far off.

Possible treatments, however, could already be available in the form of marketed or existing experimental drugs. Global public health officials, eager for a weapon to use in the midst of a global pandemic, are showing a willingness to be flexible in terms of the clinical trials and the evidence needed to prove treatments’ effectiveness.

Earlier this month, China OK’d the use of Actemra in patients with lung complications and high levels of interleukin-6, or IL-6, a protein that mediates inflammatory and immune response. High levels of IL-6 have been associated with a greater risk of death in patients with community-acquired pneumonia.

Actemra and Kevzara both block IL-6 and are prescribed for rheumatoid arthritis, a disorder in which an overactive immune system creates joint-damaging inflammation and pain. Actemra is similarly approved in conjunction with cancer cell therapy, which can sometimes trigger an immune reaction known as cytokine release syndrome.

The U.S.-based Kevzara trial is a two-part design that will initially evaluate fever and oxygen use in patients with acute respiratory distress syndrome, or ARDS. Two different dose levels will be used and compared to a placebo.

Longer-term, the trial hopes to measure prevention of death, use of ventilation, supplemental oxygen or hospitalization, but the design will be “adaptive” to determine the number of patients that will be followed and the endpoints to be used. ARDS often causes permanent lung damage and can lead to early death.

The trial aims to enroll 400 patients in the U.S. Regeneron’s partner Sanofi will handle international trial sites, naming Italy as one likely location for testing in coronavirus patients.

To get the trial underway quickly, Regeneron and Sanofi worked closely with the Food and Drug Administration and the Biomedical Advanced Research and Development Authority, the division of HHS involved in preparing for natural and man-made biological threats.

https://www.biopharmadive.com/news/regeneron-sanofi-kevzara-coronavirus-trial/574208/

The antimicrobial compounds ants excrete to defend themselves from pathogens may protect plants as well.

by Emily Makowski

Some ants produce natural antibiotic chemicals to defend themselves against fungi and bacteria. Ecologist Joachim Offenberg of Aarhus University in Denmark wondered what effect these compounds had on the health of the plants the ants called home. “We had this thought that if ants produce antibiotics, maybe these antibiotics could have an effect . . . on the diseases of the plants they walk on,” he tells The Scientist.

In a review of studies investigating the effect of ants on plant pathogens, he and fellow Aarhus ecologist Christian Damgaard found that, out of 30 plant species that were commonly inhabited by some kind of ant, 18 showed a decrease in the effects of pathogens. These included reduced bacterial load and increased germination rates enjoyed by plants inhabited by ants compared with plants of the same species that did not host ants.

Data have long confirmed that ants provide protection to their botanical hosts by eating pests, says Andreas Schramm, a microbiologist at Aarhus University who was not involved with the study. “The chemical defense of plants is really another direction that the authors quite convincingly put out here,” he says. Overall, Offenberg and Damgaard estimated that the effects of ants’ antibiotics were comparable to the benefits plants receive from the insects’ consumption of herbivorous pests.

Six of the plant species had increased pathogen incidence with ants, however, and six either had no significant difference between groups or insufficient data. Offenberg notes that a plant that hosts ants may already have a major infection that can’t be controlled with ant-produced antimicrobial compounds. Moreover, the insects can inadvertently disperse pathogens: fungal spores, for example, can cling to their legs.

https://www.the-scientist.com/the-literature/ants-produce-antibiotics-that-may-protect-plants-67146?utm_campaign=TS_DAILY%20NEWSLETTER_2020&utm_source=hs_email&utm_medium=email&utm_content=84780129&_hsenc=p2ANqtz-8vy_DyVzYey60_OuWc7ru8xDBOaFDqY8SBmNFDbnwRvOJhcMVtWw5zqUiDUV9Pe3OQONFHw1hSBij4rxpF9ER4OfSsEw&_hsmi=84780129